Health Care [ 4/12 ] | Pharmaceuticals [ 12/75 ]
NASDAQ | Common Stock
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME).
The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases.
The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025.
EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 5, 26 | -0.81 Decreased by -26.56% | -0.75 Decreased by -8.33% |
| Nov 5, 25 | -0.85 Decreased by -57.41% | -0.77 Decreased by -10.39% |
| Aug 7, 25 | -0.85 Decreased by -46.55% | -0.81 Decreased by -4.94% |
| May 6, 25 | -0.65 Decreased by -18.18% | -0.41 Decreased by -58.54% |
| Mar 5, 25 | -0.64 Decreased by -93.94% | -0.48 Decreased by -34.31% |
| Nov 8, 24 | -0.54 Decreased by -63.64% | -0.55 Increased by +1.82% |
| Aug 7, 24 | -0.58 Increased by +4.92% | -0.52 Decreased by -11.54% |
| May 8, 24 | -0.55 Increased by +1.79% | -0.42 Decreased by -30.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 620.00 K Decreased by -94.65% | -67.61 M Decreased by -63.31% | Decreased by -10.90 K% Decreased by -2.95 K% |
| Sep 30, 25 | 966.00 K Decreased by -90.82% | -59.73 M Decreased by -103.44% | Decreased by -6.18 K% Decreased by -2.12 K% |
| Jun 30, 25 | 5.33 M Decreased by -43.73% | -59.43 M Decreased by -92.78% | Decreased by -1.11 K% Decreased by -242.58% |
| Mar 31, 25 | 24.45 M Increased by +109.29% | -45.20 M Decreased by -54.33% | Decreased by -184.82% Increased by +26.26% |
| Dec 31, 24 | 11.59 M Decreased by -17.39% | -41.40 M Decreased by -193.63% | Decreased by -357.26% Decreased by -255.46% |
| Sep 30, 24 | 10.52 M Decreased by -30.77% | -29.36 M Decreased by -132.80% | Decreased by -278.99% Decreased by -236.28% |
| Jun 30, 24 | 9.48 M Increased by +4.09% | -30.83 M Decreased by -34.49% | Decreased by -325.27% Decreased by -29.21% |
| Mar 31, 24 | 11.68 M Increased by +52.08% | -29.28 M Decreased by -38.37% | Decreased by -250.63% Increased by +9.01% |